The 2018 GL was 2a. The new one is 2b. I'm not a doctor, but my take on this change (IMO), is unfounded. Safety & Efficacy are the two priorities for assessing drug treatments. Safety is definitely not an issue (12 years on the market, many studies (JELIS, MARINE, ANCHOR, REDUCEIT, EVAPORATE, RESPECT EPA).
Hell, even 8g/day dosage in CardioLink-9, PREPARE-IT 1 and PREPARE-IT 2 have demonstrated a clear SAFETY signal!
I also believe that JELIS, REDUCE-IT, CHERRY, EVAPORATE, RESPECT-EPA are conclusive enough to warrant at least a 2a efficacy evidence. Sometimes I just shake my head with many of these Committee folks.
News 
Market Data 
Discover 
